Market Place
Sourcing Support
Calidi Biotherapeutics to Join RedChip Conference April 16
15 Apr 2026 //
GLOBENEWSWIRE
Calidi Biotherapeutics Q2 2025 Financial Results and Highlights
08 Aug 2025 //
GLOBENEWSWIRE
Calidi Biotherapeutics` Live Investor Webinar and Q&A on July 24
22 Jul 2025 //
GLOBENEWSWIRE
Calidi Biotherapeutic Platform Aims to Transform Cancer Treatment
10 Jul 2025 //
GLOBENEWSWIRE
Calidi Biotherapeutics Announces Shareholder Letter from CEO
27 Jun 2025 //
GLOBENEWSWIRE
Calidi Biotherapeutics Reports Q4 and Full-Year 2024 Results
31 Mar 2025 //
GLOBENEWSWIRE
Calidi Biotherapeutics Closes $3.9M Offering and Placement
31 Mar 2025 //
GLOBENEWSWIRE
Calidi Biotherapeutics To Present RTNova Data At Conferences
24 Oct 2024 //
GLOBENEWSWIRE
Calidi Biotherapeutics Prices $2M Direct Offering
23 Oct 2024 //
GLOBENEWSWIRE
NYSE American Starts Delisting For Calidi Biotherapeutics
18 Oct 2024 //
GLOBENEWSWIRE
Calidi Biotherapeutics Gets US Patent For SuperNova Technology Platform
18 Jul 2024 //
GLOBENEWSWIRE
Calidi Biotherapeutics Adds Dr. Mark Gilbert To Medical Advisory Board
16 Jul 2024 //
GLOBENEWSWIRE
Calidi to Effect Reverse Stock Split
05 Jul 2024 //
BUSINESSWIRE
Calidi Announces Appointment of Cancer Immunotherapy Pioneer Dr. George BOD
27 Jun 2024 //
BUSINESSWIRE
Calidi Biotherapeutics To Host Live Investor Webinar And Q&A
11 Jun 2024 //
BUSINESSWIRE
Calidi Partners With SIGA For Lung Cancer And Solid Tumor Virotherapy
10 Jun 2024 //
BUSINESSWIRE
Calidi Exercises Warrants For $2.1M Gross Proceeds
31 May 2024 //
BUSINESSWIRE
Calidi Biotherapeutics Reports Q1 2024 Operating, Financial Results
14 May 2024 //
BUSINESSWIRE
Calidi Bio Presentations At ASCO 2024 Annual Meeting
01 May 2024 //
BUSINESSWIRE
Calidi Biotherapeutics to Host Investor Webinar on April 24
23 Apr 2024 //
BUSINESSWIRE
Calidi Biotherapeutics, Inc. Announces Closing of $6.1 Million Public Offering
19 Apr 2024 //
BUSINESSWIRE
Calidi Reports Fourth Quarter and Full-Year 2023 Operating and Financial Results
15 Mar 2024 //
BUSINESSWIRE
Calidi Biotherapeutics and City of Hope Announce Funding from CIRM
11 Mar 2024 //
BUSINESSWIRE
Calidi to Highlight Novel Systemic Enveloped Oncolytic Virotherapy Platform
12 Feb 2024 //
BUSINESSWIRE
Calidi Biotherapeutics Announces Presentation of Clinical Study for NeuroNova
13 Dec 2023 //
BUSINESSWIRE
Calidi Announces Appointment of David LaPré to its Board of Directors
12 Dec 2023 //
BUSINESSWIRE
Calidi Biotherapeutics Reports Third Quarter 2023 Financial Results
14 Nov 2023 //
BUSINESSWIRE
Calidi Presents Data on CLD-201 Demonstrating Inhibition of Tumor Growth
03 Nov 2023 //
BUSINESSWIRE
Calidi Biot Announces Key Leadership Promotions and New Board Appointment
01 Nov 2023 //
BUSINESSWIRE
Calidi Announces Appointment of Andrew Jackson as Chief Financial Officer
30 Oct 2023 //
BUSINESSWIRE
Calidi To Present Data Highlighting Cell-based Virotherapy Platform Technology
10 Oct 2023 //
BUSINESSWIRE
Calidi Debuts as a Publicly Traded Company Focused on Arming the Immune System
13 Sep 2023 //
BUSINESSWIRE
Calidi Biotherapeutics to Present at Baird’s Global Healthcare Conference
12 Sep 2023 //
BUSINESSWIRE
Calidi Biotherapeutics Announces Commitment of $25 Million in Series B Funding
23 Jun 2023 //
BUSINESSWIRE
Oncolytic virus startup Calidi secures $25M toward Series B round
23 Jun 2023 //
ENDPTS
Calidi Receives Funding from the CIRM to Advance SuperNova-1 and NeuroNova-2
13 Dec 2022 //
BUSINESSWIRE
Calidi Biotherapeutics to Present at the 7th Annual Oncolytic Virotherapy Summit
06 Dec 2022 //
BUSINESSWIRE
Calidi Biotherapeutics Presents Promising Data from SuperNova-1 (SNV1)
07 Nov 2022 //
BUSINESSWIRE
Calidi Biotherapeutics to Present SNV1 Data at the 2022 SITC Annual Meeting
12 Oct 2022 //
BUSINESSWIRE
Calidi Appoints David Sans, FAARM, Ph.D., MBA, as Head of Corporate Development
28 Sep 2022 //
BUSINESSWIRE
Calidi Biotherapeutics to Present at Two Upcoming Conferences
08 Sep 2022 //
BUSINESSWIRE
Calidi Biotherapeutics to Present at Jefferies Healthcare Conference
02 Jun 2022 //
BUSINESSWIRE
Calidi Bio Granted U.S. Patent for Proprietary Therapeutic Delivery Platform
24 May 2022 //
BUSINESSWIRE
Calidi Bio Appoints Alfonso "Chito" Zulueta to Its Board of Directors
04 Feb 2022 //
BUSINESSWIRE
Calidi Announces Presentation at 6th Annual Oncolytic Virotherapy Summit
25 Oct 2021 //
BUSINESSWIRE
Calidi Biotherapeutics Announces Exclusive License Agreement with City of Hope
16 Aug 2021 //
BUSINESSWIRE
Calidi Biotherapeutics Announces Agreement with Northwestern University
04 Aug 2021 //
BUSINESSWIRE
Calidi Announces European Patent Granted by EPO
01 Dec 2020 //
BUSINESSWIRE
Calidi Announces FDA Approval for COVID-19 Treatment mfg by Partner
03 Aug 2020 //
BUSINESSWIRE
Calidi Announces Appointment of Jim Schoeneck, Accomplished Biotech
01 Jul 2020 //
BUSINESSWIRE
Calidi Biotherapeutics Announces Two Abstracts Accepted for PPT at AACR 2020
22 Jun 2020 //
BUSINESSWIRE
